195 related articles for article (PubMed ID: 15383207)
1. FDG PET and PET/CT imaging in lymphoma and melanoma.
Macapinlac HA
Cancer J; 2004; 10(4):262-70. PubMed ID: 15383207
[TBL] [Abstract][Full Text] [Related]
2. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma.
Delbeke D
J Nucl Med; 1999 Apr; 40(4):591-603. PubMed ID: 10210218
[TBL] [Abstract][Full Text] [Related]
3. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience.
Tatsumi M; Cohade C; Nakamoto Y; Fishman EK; Wahl RL
Radiology; 2005 Dec; 237(3):1038-45. PubMed ID: 16304117
[TBL] [Abstract][Full Text] [Related]
4. The role of FDG-PET imaging in the management of lymphoma.
Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
[TBL] [Abstract][Full Text] [Related]
5. The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma.
Macapinlac HA
Mol Imaging Biol; 2004; 6(4):200-7. PubMed ID: 15262235
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
Kumar R; Alavi A
Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
[TBL] [Abstract][Full Text] [Related]
7. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies.
Schöder H; Larson SM; Yeung HW
J Nucl Med; 2004 Jan; 45 Suppl 1():72S-81S. PubMed ID: 14736838
[TBL] [Abstract][Full Text] [Related]
8. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
9. FDG PET Hybrid Imaging.
Becker J; Schwarzenböck SM; Krause BJ
Recent Results Cancer Res; 2020; 216():625-667. PubMed ID: 32594401
[TBL] [Abstract][Full Text] [Related]
10. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.
Allen-Auerbach M; de Vos S; Czernin J
Radiol Clin North Am; 2008 Mar; 46(2):199-211, vii. PubMed ID: 18619376
[TBL] [Abstract][Full Text] [Related]
11. Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients.
Abdulqadhr G; Molin D; Aström G; Suurküla M; Johansson L; Hagberg H; Ahlström H
Acta Radiol; 2011 Mar; 52(2):173-80. PubMed ID: 21498346
[TBL] [Abstract][Full Text] [Related]
12.
Ram-Wolff C; Vercellino L; Brice P; La Selva R; Bagot M
Eur J Dermatol; 2017 Oct; 27(5):496-504. PubMed ID: 28721937
[TBL] [Abstract][Full Text] [Related]
13. PET/CT: appropriate application in lymphoma.
Wang X
Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
[TBL] [Abstract][Full Text] [Related]
15. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
16. PET and PET/CT in management of the lymphomas.
Podoloff DA; Macapinlac HA
Radiol Clin North Am; 2007 Jul; 45(4):689-96, vii. PubMed ID: 17706533
[TBL] [Abstract][Full Text] [Related]
17. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
[TBL] [Abstract][Full Text] [Related]
18. (123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.
Cachin F; Miot-Noirault E; Gillet B; Isnardi V; Labeille B; Payoux P; Meyer N; Cammilleri S; Gaudy C; Razzouk-Cadet M; Lacour JP; Granel-Brocard F; Tychyj C; Benbouzid F; Grange JD; Baulieu F; Kelly A; Merlin C; Mestas D; Gachon F; Chezal JM; Degoul F; D'Incan M
J Nucl Med; 2014 Jan; 55(1):15-22. PubMed ID: 24263087
[TBL] [Abstract][Full Text] [Related]
19. Normal and abnormal patterns of 18F-fluorodeoxyglucose PET/CT in lymphoma.
Bar-Shalom R
Radiol Clin North Am; 2007 Jul; 45(4):677-88, vi-vii. PubMed ID: 17706532
[TBL] [Abstract][Full Text] [Related]
20. Beyond the lymph nodes: FDG-PET/CT in primary extranodal lymphoma.
Sin KM; Ho SK; Wong BY; Gill H; Khong PL; Lee EY
Clin Imaging; 2017; 42():25-33. PubMed ID: 27875758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
